Recruiting

Hyaluronic Acid

Sponsor:

University of Pennsylvania

Code:

NCT07777926

Conditions

Chin Regression

Chin Asymmetry

Jawline Contour Deficit

Eligibility Criteria

Sex: All

Age: 22 - 55

Healthy Volunteers: Accepted

Interventions

HA Filler

Study Details

Brief summary:

The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days.

The primary aim of the study is to quantify volume change of the lower face rea over time after injection of filler. The secondary aim is to collect patient related outcomes (PROs) via FACE-Q.

Participants will receive hyaluronic acid filler injections (Restylane Lyft(for contouring of the chin. Each patient will receive FDA approved dosages of filler to the lower face region to treat chin regression or chin contouring, as per FDA approved indications.

Prior to injections patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 moths for re-imaging.

Conditions

Chin Regression

Chin Asymmetry

Jawline Contour Deficit

Study ID

NCT07777926

Start date

Sep 30, 2026

Status verified date

Aug, 2026

Completion date

Dec 1, 2026

Anticipated

Primary completion date

Dec 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age 22-55
  • Patients interested in chin profile enhancement.
  • Participants must sign the informed consent form.

Exclusion Criteria:

  • Prior filler for facial contouring
  • Filler injection within the past 12 months or during duration of study
  • Prior facial cosmetic surgery (i.e.. facelift)
  • Prior facial trauma (i.e.. orbital fracture)
  • Pregnant or breastfeeding at the time of injection (initial visit)
  • Planned dental work within next 2 weeks
  • The following contraindications: patients with known hypersensitivity or severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies, gram-positive bacterial protein allergies, lidocaine allergies or other local anesthetics of the amide type
  • Patients with known bleeding disorders

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Filler

HA filler to chin region

Interventions

HA Filler

Patients will receive FDA approved dosages of filler to the lower face region to treat chin regression or contour the chin, as per FDA approved indications. Patients are limited to the maximum recommended injected dose per patient for the initial and re-treatment (touch-up) injections of 4 mL. The injected volume per injection site should not exceed 2mL, the maximum volume studied and established by the manufacturer. Prior to injections, patients will be imaged with 3-dimensional photogrammetry and take a validated survey questionnaire (FACE-Q). Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging and FACE-Q survey completion.

Primary outcome measure

  • Volume change of the lower face area at 90 days post-intervention [ Time Frame: 90 days ]

Central Contacts and Locations

Central contacts

Aamirah McCutchen

215-360-0652aamirah.mccutchen@pennmedicine.upenn.edu

Locations

Penn Medicine

Recruiting

Philadelphia, Pennsylvania, United States, 19104

More Information

Sponsor

University of Pennsylvania

Last update posted

Aug 20, 2026

Last verified

Aug, 2026

Keywords

  • jaw
  • Hyaluronic Acid
  • HA filler
  • Hyaluronic Acid filler
  • Filler
  • Cosmetic
  • face
  • dermal filler
  • chin
  • jawline

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2026-08-20.